Abstract
Extrapyramidal adverse effects (EPAs) due to neuroleptic treatment are routinely treated with anticholinergic antiparkinsonian drugs (APDs). We studied the use of these drugs in the general population exposed to neuroleptic drugs to improve our knowledge of the epidemiology of EPAs.
We selected all the neuroleptic and antiparkinsonian drug prescriptions delivered in the province of Rome (ca. 3 750 000 inhabitants) from 1986 to 1989. During the study period, 10.6% of neuroleptic-treated subjects were concurrently prescribed anticholinergic antiparkinsonian drugs. The influence of different factors on APD prescriptions was evaluated through a logistic regression model. The highest probability of receiving APDs was associated with trifluperidol treatment (odds ratio=5.0, using chlorpromazine as baseline); among the commonly prescribed neuroleptics, sulpiride, levosulpiride and tiapride chlorydrate had the lowest probability of coprescription with APDs (odds ratios less than 0.1). The probability of being prescribed anticholinergic antiparkinsonian drugs decreased with age and increased with the amount of neuroleptics prescribed.
This study surveys a very large sample using a population-based approach, whereas the same topics have previously only been studied in limited inpatient populations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:1054–1060
Donlon PT, Stenson RL (1976) Neuroleptic induced extrapyramidal symptoms. Dis Nerv Syst 37:629–635
Medina C, Kramer MD, Kurland AA (1962) Biperiden in the treatment of phenothiazine induced extrapyramidal reactions. J Am Med Assoc 182:1127–1129
Traversa G, Maggini M, Raschetti R (1991) Drug prescription monitoring systems in general practice. Ann Ist Super Sanita 27:191–206
Maggini M, Salmaso S, Spila Alegiani S, Caffari B, Raschetti R (1992) Epidemiological use of drug prescriptions as markers of disease frequency: an Italian experience. J Clin Epidemiol 44:1299–1307
Nordisk Läkemedelsstatistik/Nordic statistics on medicines 1981–1983, part II: Nordic Drug Index with classification and defined daily doses (1985) Uppsala, NLN publication No 15
Castellani L, Bozzini L, Pedrini A, Carrara F, Nasi GF, Ferrarese A, Tognoni G (1989) Prima lista italiana delle DDD di alcuni gruppi di farmaci. G Ital Farm Clinica 3:89–116
BMDP Statistical Software (1990) University of California
Raschetti R, Spila Alegiani S, Diana G, Da Cas R, Traversa G, Pasquini P (1993) Antipsychotic drug prescription in general practice in Italy. Acta Psychiatr Scand 87:317–321
Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
Korkzyn AD, Goldberg GJ (1976) Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry 39:866–869
Moleman P, Janzen G, vonBargen BA, Kappers EJ, Pepplinkhuizen L, Schmitz PIM (1986) Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. Am J Psychiatry 143:232–234
Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261–284
Lahti RA, Evans DL, Stratman NC, Figur LM (1993) Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 236:483–486
Neeper R, Richelson E, Nelson A (1991) Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain. Neuropharmacology 30:527–529
Ellenbroek BA, Prinssen EP, Cools AR (1994) The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6:1–8
Bolden-Watson C, Watson MA, Murray KD, Isackson PJ, Richelson E (1993) Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J Neurochem 61:1141–1143
Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr (1993) Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33:512–517
Diana G, Spila Alegiani S, Fortini M, Da Cas R, Raschetti R (1993) Anticholinergic Anti-Parkinson drug prescription in haloperidol-treated patients: a population-based study. Pharmacoepidemiol Drug Safety 2:73–77
Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spila-Alegiani, S., Menniti-Ippolito, F., Raschetti, R. et al. Anticholinergic antiparkinsonian therapy in outpatients treated with neuroleptic drugs: a prescription survey. Eur J Clin Pharmacol 48, 513–517 (1995). https://doi.org/10.1007/BF00194343
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00194343